Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for prevention of neutropenia during concurrent chemoradiotherapy
ChiCTR2200056819Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in esophageal cancer, bronchial carcinoma, Cervical Cancer (CC) and 3 more, sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Incidence of grade 3/4 neutropenia during concurrent chemoradiotherapy. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
esophageal cancerbronchial carcinomaCervical Cancer (CC)endometrial cancer (EC)neutropenia
Beyond the preview
Go deeper on ChiCTR2200056819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056819.